Product Request: Add Avanafil and Vardenafil to the Product Range
Hello everyone,
I would be very pleased if the active ingredients
Avanafil and
Vardenafil could be added to the product range in the future.
The primary reason is the often more favorable side effect profile, particularly of
Avanafil. This active ingredient is highly selective for the PDE5 enzyme and has minimal effect on the subtypes PDE1, PDE6, and PDE11. This selectivity is key:
- PDE1 is found, among other places, in the brain and heart muscle tissue. Inhibition of this enzyme can be associated with side effects such as headaches, flushing (facial redness), or palpitations.
- PDE6 is located in the photoreceptor cells of the retina. Inhibiting this enzyme can lead to visual disturbances (changes in color perception, light sensitivity).
- PDE11 is present in various tissues, including skeletal muscle. Its inhibition is discussed as a possible cause of muscle pain and back pain.
Since Avanafil specifically inhibits PDE5 and largely leaves the other types unaffected, the risk of precisely these side effects can be significantly lower.
Vardenafil is also more selective for PDE5 than, for example, Sildenafil, and offers a well-established profile.
This would expand the portfolio with two excellent, well-tolerated alternatives to Sildenafil and Tadalafil – a real added value for anyone who is sensitive to specific side effects.
Thank you for considering this suggestion! I am happy to engage in further discussion.